HARD TO TREAT DISEASES (PINK:HTDS) is trading up 5% at $0.0103 on huge volume of 87 million shares. Yesterday, 24 August, Hard to Treat Diseases (HTDS.PK) Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats. One of the goals of this project is to examine the potential role of Ribavirin in promoting survival of the stem cells transplanted after brain injury.
via SYMPOWERCO CORP (PINK:SYMW) Is The Top Traded OTC Stock.
